Skip to main content
Clinical Trials/NCT04580537
NCT04580537
Completed
Phase 2

Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails - a Proof-of-concept, Single-center, Prospective, Open-label, Randomized, Clinical Trial With an Intra-individual Comparison of Treatments

Bispebjerg Hospital1 site in 1 country11 target enrollmentOctober 2, 2020

Overview

Phase
Phase 2
Intervention
Enstilar
Conditions
Nail Psoriasis
Sponsor
Bispebjerg Hospital
Enrollment
11
Locations
1
Primary Endpoint
Efficacy of topical delivery of Enstilar® with and without laser pre-treatment to improve nail psoriasis
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The trial is conducted to investigate the clinical efficacy of a combination product containing calcipotriol and betamethasone formulated as an aerosol foam (Enstilar ©) for the treatment of nail psoriasis in conjunction with physical pre-treatment using a fractionally ablative carbon dioxide laser (AFL). It is hypothesized, based on preclinical data and comparable clinical trials, that laser processing prior to topical administration will lead to increased drug distribution, and thereby increase the efficacy of Enstilar® in treating nail psoriasis.

Registry
clinicaltrials.gov
Start Date
October 2, 2020
End Date
June 1, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Merete Haedersdal

Sponsor-Investigator [Consultant in dermatology, Clinical professor]

Bispebjerg Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Laser-assisted Enstilar delivery

Ablative fractional laser (AFL) pre-treatment + daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)

Intervention: Enstilar

Laser-assisted Enstilar delivery

Ablative fractional laser (AFL) pre-treatment + daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)

Intervention: Ablative fractional laser

Enstilar

Daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)

Intervention: Enstilar

Outcomes

Primary Outcomes

Efficacy of topical delivery of Enstilar® with and without laser pre-treatment to improve nail psoriasis

Time Frame: Day1 : Week 24

Change from baseline to end of treatment in N-NAIL score per nail for each treatment

Secondary Outcomes

  • Safety profile and local tissue response to laser treatment and Enstilar® application(Day 1 : Week 24)

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting
Phase 1
An evaluation of the effect of laser pretreatment for treatment of nail psoriasis using Enstilar® foamail psoriasisMedDRA version: 20.0Level: HLTClassification code 10065874Term: Psoriatic conditionsSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.1Level: PTClassification code 10037162Term: Psoriatic arthropathySystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0Level: PTClassification code 10028703Term: Nail psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 22.0Level: LLTClassification code 10028691Term: Nail discolorationSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.1Level: LLTClassification code 10006373Term: Brittle nailsSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: LLTClassification code 10028689Term: Nail changesSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: LLTClassification code 10028690Term: Nail deformationSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.1Level: LLTClassification code 10049281Term: Nail lossSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: LLTClassification code 10064253Term: Nail painSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.1Level: LLTClassification code 10064768Term: Nail growth increasedSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.1Level: LLTClassification code 10065260Term: Splitting nailsSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.0Level: LLTClassification code 10069831Term: Broken nailsSyTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2019-002960-29-DKMerete Haedersdal [Bispebjerg Hospital]11
Active, not recruiting
Not Applicable
Clinical Study to Evaluate Alexandrite Laser for the Treatment of Acne ScarsAcne Scars
NCT04807179Cynosure, Inc.39
Recruiting
Not Applicable
The effect of laser on soft tissue anesthesiaThe effect of laser in reversing local anesthesia.Local anaesthetics (Adverse effect in therapeutic use)
IRCT20180804040693N1aser Research Center of Dentistry, Tehran University of Medical Sciences34
Active, not recruiting
Not Applicable
Clinical Evaluation to Demonstrate the Safety and Performance of the Candela PicoWay System™WrinklePigmented Lesions
NCT04727099Candela Corporation50
Completed
Not Applicable
Measurement and Treatment of Back PainBack Pain
NCT06245863State University of Minas Gerais50